Literature DB >> 27538963

Mouse models of Down syndrome: gene content and consequences.

Meenal Gupta1, A Ranjitha Dhanasekaran1, Katheleen J Gardiner2,3,4.   

Abstract

Down syndrome (DS), trisomy of human chromosome 21 (Hsa21), is challenging to model in mice. Not only is it a contiguous gene syndrome spanning 35 Mb of the long arm of Hsa21, but orthologs of Hsa21 genes map to segments of three mouse chromosomes, Mmu16, Mmu17, and Mmu10. The Ts65Dn was the first viable segmental trisomy mouse model for DS; it is a partial trisomy currently popular in preclinical evaluations of drugs for cognition in DS. Limitations of the Ts65Dn are as follows: (i) it is trisomic for 125 human protein-coding orthologs, but only 90 of these are Hsa21 orthologs and (ii) it lacks trisomy for ~75 Hsa21 orthologs. In recent years, several additional mouse models of DS have been generated, each trisomic for a different subset of Hsa21 genes or their orthologs. To best exploit these models and interpret the results obtained with them, prior to proposing clinical trials, an understanding of their trisomic gene content, relative to full trisomy 21, is necessary. Here we first review the functional information on Hsa21 protein-coding genes and the more recent annotation of a large number of functional RNA genes. We then discuss the conservation and genomic distribution of Hsa21 orthologs in the mouse genome and the distribution of mouse-specific genes. Lastly, we consider the strengths and weaknesses of mouse models of DS based on the number and nature of the Hsa21 orthologs that are, and are not, trisomic in each, and discuss their validity for use in preclinical evaluations of drug responses.

Entities:  

Mesh:

Year:  2016        PMID: 27538963      PMCID: PMC5471624          DOI: 10.1007/s00335-016-9661-8

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  151 in total

Review 1.  Non-coding RNAs: hope or hype?

Authors:  Alexander Hüttenhofer; Peter Schattner; Norbert Polacek
Journal:  Trends Genet       Date:  2005-05       Impact factor: 11.639

2.  miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells.

Authors:  Z Yang; Y Han; K Cheng; G Zhang; X Wang
Journal:  Cell Prolif       Date:  2014-10-27       Impact factor: 6.831

3.  Genetic dissection of the Down syndrome critical region.

Authors:  Xiaoling Jiang; Chunhong Liu; Tao Yu; Li Zhang; Kai Meng; Zhuo Xing; Pavel V Belichenko; Alexander M Kleschevnikov; Annie Pao; Jennifer Peresie; Sarah Wie; William C Mobley; Y Eugene Yu
Journal:  Hum Mol Genet       Date:  2015-09-15       Impact factor: 6.150

4.  Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice.

Authors:  Lisa E Olson; Randall J Roper; Crystal L Sengstaken; Elizabeth A Peterson; Veronica Aquino; Zygmunt Galdzicki; Richard Siarey; Mikhail Pletnikov; Timothy H Moran; Roger H Reeves
Journal:  Hum Mol Genet       Date:  2007-03-05       Impact factor: 6.150

5.  D21S418E identifies a cAMP-regulated gene located on chromosome 21q22.3 that is expressed in placental syncytiotrophoblast and choriocarcinoma cells.

Authors:  S Kido; N Sakuragi; M P Bronner; R Sayegh; R Berger; D Patterson; J F Strauss
Journal:  Genomics       Date:  1993-07       Impact factor: 5.736

6.  The molecular basis of glutamate formiminotransferase deficiency.

Authors:  John F Hilton; Karen E Christensen; David Watkins; Benjamin A Raby; Yannick Renaud; Susanna de la Luna; Xavier Estivill; Robert E MacKenzie; Thomas J Hudson; David S Rosenblatt
Journal:  Hum Mutat       Date:  2003-07       Impact factor: 4.878

Review 7.  The mammalian anti-proliferative BTG/Tob protein family.

Authors:  G Sebastiaan Winkler
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

Review 8.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

9.  Massively parallel sequencing reveals the complex structure of an irradiated human chromosome on a mouse background in the Tc1 model of Down syndrome.

Authors:  Susan M Gribble; Frances K Wiseman; Stephen Clayton; Elena Prigmore; Elizabeth Langley; Fengtang Yang; Sean Maguire; Beiyuan Fu; Diana Rajan; Olivia Sheppard; Carol Scott; Heidi Hauser; Philip J Stephens; Lucy A Stebbings; Bee Ling Ng; Tomas Fitzgerald; Michael A Quail; Ruby Banerjee; Kai Rothkamm; Victor L J Tybulewicz; Elizabeth M C Fisher; Nigel P Carter
Journal:  PLoS One       Date:  2013-04-15       Impact factor: 3.240

10.  miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9.

Authors:  Andrea Feliciano; Josep Castellvi; Ana Artero-Castro; Jose A Leal; Cleofé Romagosa; Javier Hernández-Losa; Vicente Peg; Angels Fabra; Francisco Vidal; Hiroshi Kondoh; Santiago Ramón Y Cajal; Matilde E Lleonart
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

View more
  55 in total

1.  Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome.

Authors:  Verónica Vidal; Susana García-Cerro; Paula Martínez; Andrea Corrales; Sara Lantigua; Rebeca Vidal; Noemí Rueda; Laurence Ozmen; Maria-Clemencia Hernández; Carmen Martínez-Cué
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

2.  Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  FASEB J       Date:  2019-06-10       Impact factor: 5.191

3.  Proteomic analysis of six- and twelve-month hippocampus and cerebellum in a murine Down syndrome model.

Authors:  Guido N Vacano; David S Gibson; Abdullah Arif Turjoman; Jeremy W Gawryluk; Jonathan D Geiger; Mark Duncan; David Patterson
Journal:  Neurobiol Aging       Date:  2017-11-26       Impact factor: 4.673

Review 4.  Influence of allelic differences in Down syndrome.

Authors:  Randall J Roper; Laura Hawley; Charles R Goodlett
Journal:  Prog Brain Res       Date:  2019-10-24       Impact factor: 2.453

Review 5.  Human Models Are Needed for Studying Human Neurodevelopmental Disorders.

Authors:  Xinyu Zhao; Anita Bhattacharyya
Journal:  Am J Hum Genet       Date:  2018-12-06       Impact factor: 11.025

6.  Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society.

Authors:  Jean-Maurice Delabar; Bernadette Allinquant; Diana Bianchi; Tom Blumenthal; Alain Dekker; Jamie Edgin; John O'Bryan; Mara Dierssen; Marie-Claude Potier; Frances Wiseman; Faycal Guedj; Nicole Créau; Roger Reeves; Katheleen Gardiner; Jorge Busciglio
Journal:  Mol Syndromol       Date:  2016-09-16

7.  Touchscreen learning deficits in Ube3a, Ts65Dn and Mecp2 mouse models of neurodevelopmental disorders with intellectual disabilities.

Authors:  P T Leach; J N Crawley
Journal:  Genes Brain Behav       Date:  2018-02-15       Impact factor: 3.449

8.  JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.

Authors:  Kathryn D Tuttle; Katherine A Waugh; Paula Araya; Ross Minter; David J Orlicky; Michael Ludwig; Zdenek Andrysik; Matthew A Burchill; Beth A J Tamburini; Colin Sempeck; Keith Smith; Ross Granrath; Dayna Tracy; Jessica Baxter; Joaquin M Espinosa; Kelly D Sullivan
Journal:  Cell Rep       Date:  2020-11-17       Impact factor: 9.423

9.  Prefrontal-hippocampal functional connectivity encodes recognition memory and is impaired in intellectual disability.

Authors:  Maria Alemany-González; Thomas Gener; Pau Nebot; Marta Vilademunt; Mara Dierssen; M Victoria Puig
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-11       Impact factor: 11.205

10.  When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.

Authors:  Jill M Pulley; Rebecca N Jerome; Nicole M Zaleski; Jana K Shirey-Rice; Andrea J Pruijssers; Robert R Lavieri; Somsundaram N Chettiar; Helen M Naylor; David M Aronoff; David A Edwards; Colleen M Niswender; Laura L Dugan; Leslie J Crofford; Gordon R Bernard; Kenneth J Holroyd
Journal:  Assay Drug Dev Technol       Date:  2017-12-01       Impact factor: 1.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.